Literature DB >> 15482389

Do risk factors for lactic acidosis influence dosing of metformin?

S Millican1, N Cottrell, B Green.   

Abstract

BACKGROUND: Metformin is commonly prescribed to treat type 2 diabetes mellitus, however it is associated with the potentially lethal condition of lactic acidosis. Prescribing guidelines have been developed to minimize the risk of lactic acidosis development, although some suggest they are inappropriate and have created confusion amongst prescribers. The aim of this study was to investigate whether metformin dose was influenced by the presence of risk factors for lactic acidosis.
METHODS: The study was prospective, and retrieved information from patients admitted to hospital who were prescribed metformin at their time of admission.
RESULTS: Eighty-three patients were included in the study, 60 of whom had a least one risk factor for lactic acidosis. Of those 60 patients, 78.3% had a dose adjustment, with renal impairment, hepatic impairment, surgery and use of radiological contrast media--the risk factors most likely to result in a dose adjustment. When dose adjustments did occur, metformin was withheld on 88.7% of occasions.
CONCLUSION: Metformin dose was influenced by the presence of risk factors for lactic acidosis, although it was dependent upon the number and particular risk factor/s present.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482389     DOI: 10.1111/j.1365-2710.2004.00589.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  2 in total

Review 1.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

2.  Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome.

Authors:  Juraporn Pongwecharak; Nawatsanan Tengmeesri; Nongluck Malanusorn; Matshamon Panthong; Nantida Pawangkapin
Journal:  Pharm World Sci       Date:  2009-05-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.